gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Transmembrane protease, serine 2

This gene encodes a protein that belongs to the serine protease family. The encoded protein contains a type II transmembrane domain, a receptor class A domain, a scavenger receptor cysteine-rich domain and a protease domain. Serine proteases are known to be involved in many physiological and pathological processes. This gene was demonstrated to be up-regulated by androgenic hormones in prostate cancer cells and down-regulated in androgen-independent prostate cancer tissue. The protease domain of this protein is thought to be cleaved and secreted into cell media after autocleavage. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2008] (from NCBI)
Top mentioned proteins: CAN, MEN, HAD, PTEN, POLYMERASE
Papers using TMPRSS2 antibodies
An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression.
Bauer Joseph Alan, In PLoS ONE, 2009
... TMPRSS2-ERG fusion transcript isoforms (III, III+72, VI, VI+72) [18] or ERG cDNA (RC218892, OriGene Technologies, Inc.) were transfected ...
Papers on TMPRSS2
Cytoplasmic accumulation of ELAVL1 is an independent predictor of biochemical recurrence associated with genomic instability in prostate cancer.
Krech et al., Hamburg, Germany. In Prostate, Feb 2016
ELAVL1 positivity was more frequent in cancers harboring TMPRSS2:ERG fusions found by FISH (78%) or showing immunohistochemical ERG expression (74%) than in cancers without ERG rearrangement (63%) or ERG expression (58%, P < 0.0001 each).
Assembly of methylated KDM1A and CHD1 drives androgen receptor-dependent transcription and translocation.
Schüle et al., Freiburg, Germany. In Nat Struct Mol Biol, Feb 2016
TMPRSS2-ERG gene fusions found in human prostate tumors are a hallmark of chromoplexy.
Two paths for stabilization of ERG in prostate carcinogenesis: TMPRSS2-ERG fusions and speckle-type pox virus and zinc finger protein mutations.
Wang et al., Pittsburgh, United States. In Asian J Androl, Feb 2016
In addition, N-terminal truncated ERG proteins encoded by the most frequently identified TMPRSS2-ERG rearrangements in prostate cancer (T1-E4 and T1-E5) were resistant to SPOP-mediated degradation, resulting in the stabilization of truncated ERG proteins.
Identification of Combinatorial Genomic Abnormalities Associated with Prostate Cancer Early Recurrence.
Fang et al., Sherbrooke, Canada. In J Mol Diagn, Feb 2016
We tested the prognostic utility of a three-marker fluorescent in situ hybridization panel (TMPRSS2/ERG rearrangements, AR gain, and PTEN deletion) in a retrospective cohort (n = 210; median follow-up, 5.7 years).
Urine TMPRSS2: ERG Fusion Transcript as a Biomarker for Prostate Cancer: Literature Review.
Cormio et al., Foggia, Italy. In Clin Genitourin Cancer, Jan 2016
In this study, we analyzed the current role of urinary gene fusion transcripts involving v-ets erythroblastosis virus E26 oncogene homolog, commonly known as ERG, and the androgen-regulated gene transmembrane protease, serine 2 (TMPRSS2), as a biomarker for PCa.
Epigenomic profiling of prostate cancer identifies differentially methylated genes in TMPRSS2:ERG fusion-positive versus fusion-negative tumors.
Stanford et al., Seattle, United States. In Clin Epigenetics, 2014
BACKGROUND: About half of all prostate cancers harbor the TMPRSS2:ERG (T2E) gene fusion.
Current State of ERG as Biomarker in Prostatic Adenocarcinoma.
Szasz et al., Budapest, Hungary. In Curr Cancer Drug Targets, 2014
In this review we briefly discuss the possible biomarkers of prostate cancer among them we focus and analyze the relevance of TMPRSS2-ERG fusion gene in line with ERG expression in the diagnosis of prostate cancer.
Current biomarkers for diagnosing of prostate cancer.
Ralla et al., Berlin, Germany. In Future Oncol, 2014
While the detection of alterations of the androgen-regulated TMPRSS2 and ETS transcription factor genes in tissue of ˜50% of all PCa patients was one research milestone, the urinary assay should only be used in combination with PCA3.
Potential Utility of Novel Biomarkers in Active Surveillance of Low-Risk Prostate Cancer.
Hong et al., Ch'unch'ŏn, South Korea. In Biomed Res Int, 2014
PCA3 and TMPRSS2:ERG had additional independent predictive value for the prediction of PCa detection and progression, although PCA3 was limited in predicting aggressive cancer.
Organoid cultures derived from patients with advanced prostate cancer.
Chen et al., New York City, United States. In Cell, 2014
The first seven fully characterized organoid lines recapitulate the molecular diversity of prostate cancer subtypes, including TMPRSS2-ERG fusion, SPOP mutation, SPINK1 overexpression, and CHD1 loss.
Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.
Chinnaiyan et al., Ann Arbor, United States. In Nature, 2014
By contrast with MDV3100, JQ1 functions downstream of AR, and more potently abrogated BRD4 localization to AR target loci and AR-mediated gene transcription, including induction of the TMPRSS2-ERG gene fusion and its oncogenic activity.
Targeted androgen pathway suppression in localized prostate cancer: a pilot study.
Montgomery et al., Seattle, United States. In J Clin Oncol, 2014
Staining for AR and the androgen-regulated genes prostate-specific antigen and TMPRSS2 was strongly suppressed in benign glands and moderately in malignant glands (P < .05
TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia.
Rubin et al., Memphis, United States. In J Clin Oncol, 2014
PURPOSE: High-grade prostatic intraepithelial neoplasia (HGPIN) is considered a precursor lesion of prostate cancer (PCa).
A Quest to Identify Prostate Cancer Circulating Biomarkers with a Bench-to-Bedside Potential.
Hlatky et al., Boston, United States. In J Biomark, 2013
Some of the circulating biomarkers like PCA3, IL-6, and TMPRSS2-ERG are now detectable by commercially available kits while others like microRNAs (miR-21, -221, -141) and exosomes hold potential to become available as multiplexed assays.
Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer.
Schlomm et al., Heidelberg, Germany. In Cancer Cell, 2013
Whereas EO-PCAs harbored a prevalence of balanced SRs, with a specific abundance of androgen-regulated ETS gene fusions including TMPRSS2:ERG, elderly-onset PCAs displayed primarily non-androgen-associated SRs.
Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers.
Joshua et al., Toronto, Canada. In Bju Int, 2012
Blood mRNA levels of prostate cancer genes may represent a novel aspect of monitoring prostate cancer and have implications for the understanding of tumour-derived mRNA
The relationship of TMPRSS2-ERG gene fusion between primary and metastatic prostate cancers.
Czerniak et al., Houston, United States. In Hum Pathol, 2012
This study demonstrates a close relationship of the TMPRSS2-ERG gene fusion status between primary and metastatic prostate cancer.
Cathepsins B and L activate Ebola but not Marburg virus glycoproteins for efficient entry into cell lines and macrophages independent of TMPRSS2 expression.
Pöhlmann et al., Hannover, Germany. In Virology, 2012
Cathepsins B and L activate Ebola but not Marburg virus glycoproteins for efficient entry into cell lines and macrophages independent of TMPRSS2 expression.
Influenza and SARS-coronavirus activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory and gastrointestinal tracts.
Soilleux et al., Göttingen, Germany. In Plos One, 2011
TMPRSS2 and HAT are expressed by important influenza and SARS-coronavirus target cells and could thus support viral spread in the human host.
The oncogenic gene fusion TMPRSS2: ERG is not a diagnostic or prognostic marker for ovarian cancer.
Liu et al., Houston, United States. In Int J Clin Exp Pathol, 2010
Suggest that the oncogenic gene fusion TMPRSS2:ERG does not occur in ovarian cancer relative to prostate cancer.
share on facebooktweetadd +1mail to friends